G1 Therapeutics (GTHX) Stock Price, News & Analysis

Company Overview

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Key Stats

• Today's Range: $7.15 to $7.15
• 50-Day Range: $7.08 to $7.15
• 52-Week Range: $1.08 to $7.19
• Volume: N/A
• Average Volume: 1.70 million shs
• Market Capitalization: $373.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

GTHX Stock Analysis - Frequently Asked Questions

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The business earned $14.48 million during the quarter, compared to analyst estimates of $15.21 million. G1 Therapeutics had a negative net margin of 76.93% and a negative trailing twelve-month return on equity of 136.98%.
Read the conference call transcript.

When did G1 Therapeutics IPO?

G1 Therapeutics (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that G1 Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX), Pfizer (PFE), NVIDIA (NVDA) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/01/2024
• Today: 6/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GTHX
• CIK: 1560241
• Web: www.g1therapeutics.com
• Phone: (919) 213-9835
• Fax: 919-741-5830
• Employees: 170
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.97 million
• Net Margins: -76.93%
• Pretax Margin: -73.83%
• Return on Equity: -136.98%
• Return on Assets: -39.33%

Debt

• Debt-to-Equity Ratio: 1.34
• Current Ratio: 2.48
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $58.20 million
• Price / Sales: 6.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.68 per share
• Price / Book: 10.51

Miscellaneous

• Outstanding Shares: 52,281,000
• Free Float: 49,087,000
• Market Cap: $373.81 million
• Optionable: Optionable
• Beta: 1.66